-
Phase 2 Trial of Levosimendan to Treat PH Linked to Specific Heart Failure Moving Forward
Plans for a Phase 2 clinical trial of levosimendan, a proposed treatment for pulmonary hypertension associated with heart failure and preserved ejection fraction, will soon be submitted to the U.S. Food and Drug Administration for approval, Tenax Therapeutics announced.
In a pre-application meeting with company executives, the FDA supported the study’s proposed design and measures that will be used to demonstrate proof-of-concept in people with pulmonary hypertension associated with heart failure and preserved ejection fraction, or PH-HFpEF patients, Tenax said in a press release.
An Investigational New Drug application will soon be submitted, and the trial is expected to open in the summer.
Read more about Levosimendan as a treatment for PH here: “Phase 2 Trial of Levosimendan to Treat PH Linked to Specific Heart Failure Moving Forward“
What are your thoughts on this possible treatment? Join the discussion below.
-
0 Replies
Sorry, there were no replies found.
Log in to reply.